Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor. Issue 4 (3rd July 2016)

• Record Type: Journal Article
• Authors: Yamasaki, Yuichi; Takei, Syuji; Imanaka, Hiroyuki; Nerome, Yasuhito; Kubota, Tomohiro; Nonaka, Yukiko; Akaike, Harumi; Takezaki, Tomoko; Kawano, Yoshifumi
• Is Part Of: Modern rheumatology. Volume 26:Issue 4(2016)
• Page Start: 551
• Page End: 556
• Publication Date: 2016-07-03
• Subjects: DAS-28 -- Long-term remission -- Oligo/polyarticular JIA -- S100A12 -- VEGF; Rheumatology -- Periodicals; 616.723005
• DOI: 10.3109/14397595.2015.1109784
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives : This study aimed to evaluate the usefulness of S100A12 and vascular endothelial growth factor (VEGF) for predicting the stability of remission for discontinuing methotrexate (MTX) and/or biological agents in Japanese patients with oligo/polyarticular juvenile idiopathic arthritis (JIA). Methods : Forty-four patients with oligo/polyarticular JIA who received MTX with or without biological agents were enrolled. Serum concentration of both S100A12 and VEGF were simultaneously evaluated by ELISA in active and in remission phase determined by activity markers including DAS-28. Results : S100A12 and VEGF were correlated with DAS-28. Of the 22 patients with oligo/polyarticular JIA in clinical remission, 13 patients with low S100A12 and VEGF concentrations could discontinue treatment without relapse over 2 years. However, nine patients without low S100A12 and VEGF concentrations relapsed afterwards, even though they had been in clinical remission. The cut-off levels of S100A12 and VEGF for division into two groups of the maintenance remission and relapse groups were 177 ng/ml and 158 pg/ml, respectively. Conclusions : S100A12 and VEGF are useful markers for assessing disease activity of oligo/polyarticular JIA in remission phase. These markers should be kept low when clinicians consider tapering or discontinuing treatments in oligo/polyarticular JIA patients.